Cargando…
Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice
SIMPLE SUMMARY: The concept of utilizing mesenchymal stem cells for the treatment of central nervous system disorders has progressed from preclinical studies to clinical trials. While promising, the effectiveness of cell therapy is hampered by the route used to deliver cells into the brain. In this...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963187/ https://www.ncbi.nlm.nih.gov/pubmed/33803160 http://dx.doi.org/10.3390/cancers13051169 |
_version_ | 1783665584583475200 |
---|---|
author | Aguilera, Yolanda Mellado-Damas, Nuria Olmedo-Moreno, Laura López, Víctor Panadero-Morón, Concepción Benito, Marina Guerrero-Cázares, Hugo Márquez-Vega, Catalina Martín-Montalvo, Alejandro Capilla-González, Vivian |
author_facet | Aguilera, Yolanda Mellado-Damas, Nuria Olmedo-Moreno, Laura López, Víctor Panadero-Morón, Concepción Benito, Marina Guerrero-Cázares, Hugo Márquez-Vega, Catalina Martín-Montalvo, Alejandro Capilla-González, Vivian |
author_sort | Aguilera, Yolanda |
collection | PubMed |
description | SIMPLE SUMMARY: The concept of utilizing mesenchymal stem cells for the treatment of central nervous system disorders has progressed from preclinical studies to clinical trials. While promising, the effectiveness of cell therapy is hampered by the route used to deliver cells into the brain. In this context, intranasal cell administration has boomed over the past few years as an effective cell delivery method. However, comprehensive safety studies are required before translation to the clinic. Our study shed light on how intranasally administrated mesenchymal stem cells may be used to safely treat neurological disorders. ABSTRACT: Mesenchymal stem cell (MSC)-based therapy is a promising therapeutic approach in the management of several pathologies, including central nervous system diseases. Previously, we demonstrated the therapeutic potential of human adipose-derived MSCs for neurological sequelae of oncological radiotherapy using the intranasal route as a non-invasive delivery method. However, a comprehensive investigation of the safety of intranasal MSC treatment should be performed before clinical applications. Here, we cultured human MSCs in compliance with quality control standards and administrated repeated doses of cells into the nostrils of juvenile immunodeficient mice, mimicking the design of a subsequent clinical trial. Short- and long-term effects of cell administration were evaluated by in vivo and ex vivo studies. No serious adverse events were reported on mouse welfare, behavioral performances, and blood plasma analysis. Magnetic resonance study and histological analysis did not reveal tumor formation or other abnormalities in the examined organs of mice receiving MSCs. Biodistribution study reveals a progressive disappearance of transplanted cells that was further supported by an absent expression of human GAPDH gene in the major organs of transplanted mice. Our data indicate that the intranasal application of MSCs is a safe, simple and non-invasive strategy and encourage its use in future clinical trials. |
format | Online Article Text |
id | pubmed-7963187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79631872021-03-17 Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice Aguilera, Yolanda Mellado-Damas, Nuria Olmedo-Moreno, Laura López, Víctor Panadero-Morón, Concepción Benito, Marina Guerrero-Cázares, Hugo Márquez-Vega, Catalina Martín-Montalvo, Alejandro Capilla-González, Vivian Cancers (Basel) Article SIMPLE SUMMARY: The concept of utilizing mesenchymal stem cells for the treatment of central nervous system disorders has progressed from preclinical studies to clinical trials. While promising, the effectiveness of cell therapy is hampered by the route used to deliver cells into the brain. In this context, intranasal cell administration has boomed over the past few years as an effective cell delivery method. However, comprehensive safety studies are required before translation to the clinic. Our study shed light on how intranasally administrated mesenchymal stem cells may be used to safely treat neurological disorders. ABSTRACT: Mesenchymal stem cell (MSC)-based therapy is a promising therapeutic approach in the management of several pathologies, including central nervous system diseases. Previously, we demonstrated the therapeutic potential of human adipose-derived MSCs for neurological sequelae of oncological radiotherapy using the intranasal route as a non-invasive delivery method. However, a comprehensive investigation of the safety of intranasal MSC treatment should be performed before clinical applications. Here, we cultured human MSCs in compliance with quality control standards and administrated repeated doses of cells into the nostrils of juvenile immunodeficient mice, mimicking the design of a subsequent clinical trial. Short- and long-term effects of cell administration were evaluated by in vivo and ex vivo studies. No serious adverse events were reported on mouse welfare, behavioral performances, and blood plasma analysis. Magnetic resonance study and histological analysis did not reveal tumor formation or other abnormalities in the examined organs of mice receiving MSCs. Biodistribution study reveals a progressive disappearance of transplanted cells that was further supported by an absent expression of human GAPDH gene in the major organs of transplanted mice. Our data indicate that the intranasal application of MSCs is a safe, simple and non-invasive strategy and encourage its use in future clinical trials. MDPI 2021-03-09 /pmc/articles/PMC7963187/ /pubmed/33803160 http://dx.doi.org/10.3390/cancers13051169 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Aguilera, Yolanda Mellado-Damas, Nuria Olmedo-Moreno, Laura López, Víctor Panadero-Morón, Concepción Benito, Marina Guerrero-Cázares, Hugo Márquez-Vega, Catalina Martín-Montalvo, Alejandro Capilla-González, Vivian Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice |
title | Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice |
title_full | Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice |
title_fullStr | Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice |
title_full_unstemmed | Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice |
title_short | Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice |
title_sort | preclinical safety evaluation of intranasally delivered human mesenchymal stem cells in juvenile mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963187/ https://www.ncbi.nlm.nih.gov/pubmed/33803160 http://dx.doi.org/10.3390/cancers13051169 |
work_keys_str_mv | AT aguilerayolanda preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT melladodamasnuria preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT olmedomorenolaura preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT lopezvictor preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT panaderomoronconcepcion preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT benitomarina preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT guerrerocazareshugo preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT marquezvegacatalina preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT martinmontalvoalejandro preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice AT capillagonzalezvivian preclinicalsafetyevaluationofintranasallydeliveredhumanmesenchymalstemcellsinjuvenilemice |